[A19-85] Trifluridine/tipiracil (gastric cancer) - Benefit assessment according to §35a Social Code Book V
Last updated 02.04.2020
Commission awarded on 02.10.2019 by the Federal Joint Committee (G-BA).
Adult patients with metastatic gastric cancer including adenocarcinoma of the gastroesophageal junction, who have been previously treated with at least 2 prior systemic treatment regimens for advanced disease
Hint of considerable added benefit
The current version 1.1 of the dossier assessment replaces version 1.0 published on 2020-01-15.
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
|A20-35||Trifluridine/tipiracil (colorectal cancer) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)||Commission completed|
|A16-54||Trifluridine/tipiracil (colorectal cancer) - Benefit assessment according to §35a Social Code Book V||Commission completed|
|A16-77||Trifluridine/tipiracil (colorectal cancer) - Addendum to Commission A16-54||Commission completed|